Drug-related problems in patients with osteoporosis

Ilić, Dušan; Bukumirić, Zoran; Janković, Slobodan M.

doi:10.2298/vsp140909090i

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that a significant number of patients did not adhere to the direct recommendations of the doctors concerning the intake of drugs, which indicates a low adherence of patients to the treatment. The main reasons for refusal of pharmacotherapy mentioned by patients, were the occurrence of adverse effects (48.5% of the total number of patients who did not adhere to the prescribed therapy), the belief that the drugs for the OP treatment cause more harm than benefit (68.9%), neglecting the impact of OP and its complications on the general state of health (57.3%) [57].…”

Section: Drps In Osteoporosis Pharmacotherapymentioning

confidence: 99%

Review of publications on drug-related problems investigations in osteoporosis patients

Egorova,

Beitullaev,

Matveev

et al. 2024

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

A chronic form of osteoporosis (OP) substantiates a long-term pharmacotherapy of patients, which increases the risk of adverse drug reactions (ADRs) during the therapy. The enhancement of requirements to the quality of safety monitoring carried out in the context of pharmacovigilance and the newly identified safety problems require an improvement of the system of quality control of medicinal products (MPs).The aim of the work was to review the application of a new promising method for monitoring the drug safety – the system of Drug-Related Problems (DRP) in the osteoporosis pharmacotherapy.Materials and methods. The following databases and search engines were used to retrieve scientific papers by Russian and foreign authors: PubMed, elibrary.ru, Google Scholar, CyberLeninka, Russian National Library. The information sources were searched using the following keywords and word combinations: “drug-related problems”, “drug safety”, “osteoporosis” (in Russian and English, respectively), as well as the corresponding MeSH terms.Results. The application of DRP system in the health care of different countries was reviewed, and the risk factors of the problems associated with the use of MPs, the appropriate interventions in case of the detection of high DRP values were investigated. The study of the problems associated with the use of MPs for the treatment of OP during the complex pharmacotherapy made it possible to determine the feasibility of using this method to improve the safety and effectiveness of this kind of treatment in patients.Conclusion. The analysis of emerging DRPs makes it possible to increase patients’ adherence to the treatment and stop the ADRs. This improves the quality of life of patients and increases the effectiveness of pharmacotherapy. The introduction of such a method of the drug safety research into the system of pharmacovigilance of the Russian Federation is an important step in the development of personalized medicine. A further study of problems associated with the use of drugs in OP patients will also help to reduce the risks arising during the combination pharmacotherapy.

show abstract

Section: Drps In Osteoporosis Pharmacotherapymentioning

confidence: 99%

Review of publications on drug-related problems investigations in osteoporosis patients

Egorova,

Beitullaev,

Matveev

et al. 2024

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

show abstract

“…Nevertheless, a combination of teriparatide and denosumab can increase bone mineral density more efficaciously than monotherapy with either agent, especially in postmenopausal women with osteoporosis [18,19] . In some ways, these drugs have succeeded, but highly publicized side effects are causing patients to shy away from these bisphosphonates [20] or daily subcutaneous injectable drugs. Therefore, there is a strong medical need to look for new anti-osteoporosis drugs.…”

Section: Introductionmentioning

confidence: 99%

Dual roles of QOA-8a in antiosteoporosis: a combination of bone anabolic and anti-resorptive effects

Shen

Cui

et al. 2017

Acta Pharmacol Sin

View full text Add to dashboard Cite

Osteoporotic treatments have largely depended on antiresorptive or anabolic drugs; but the former also suppresses new bone formation, and the latter only includes human parathyroid hormone. There is no drug that has a dual effect to inhibit bone resorption and to stimulate bone formation simultaneously. Here, we report a small molecule, a quinoxaline derivative of oleanolic acid (QOA-8a) that plays such dual roles in osteoblasts and osteoclasts in the treatment of osteoporosis. Osteoclast differentiation was induced by incubation of primary mouse bone marrow-derived macrophages in the presence of RANKL and M-CSF, treatment with QOA-8a dose-dependently inhibited the osteoclast formation with an IC value of 0.098 μmol/L. QOA-8a also directly acted on osteoblasts, and stimulated new bone formation in murine calvarial bones in vitro and in vivo. In an OVX rat model, administration of QOA-8a (1, 5 mg·kg·d, po) for 16 weeks effectively prevented OVX-induced bone loss, accompanied by decreased serum levels of the bone resorption marker CTX-1 and increased serum levels of osteoblast marker N-MID-OT. Meaningfully, our preliminary study revealed that QOA-8a down-regulated the ERK1/2 signal in osteoclasts and up-regulated the signal in osteoblasts. QOA-8a showed dual functions in both animal and human osteoclastogenesis and osteoblastogenesis. Our results demonstrate that QOA-8a might serve as a lead compound with a dual function of bone anabolic and anti-resorptive effects in the development of anti-osteoporosis agents.

show abstract

Chinese Herbal Medicine for Osteoporosis: A Meta-analysis of Randomized Controlled Trials

Jin

Mao

et al. 2017

Journal of Clinical Densitometry

View full text Add to dashboard Cite

Drug-related problems in patients with osteoporosis

Abstract: The effectiveness of osteoporosis treatment is decreased by several drug-related problems encountered by both physicians and patients. However, the majority of the drug-related problems could be greatly influenced by appropriate educational programs.

Cited by 4 publications

References 20 publications

Review of publications on drug-related problems investigations in osteoporosis patients

Review of publications on drug-related problems investigations in osteoporosis patients

Dual roles of QOA-8a in antiosteoporosis: a combination of bone anabolic and anti-resorptive effects

Chinese Herbal Medicine for Osteoporosis: A Meta-analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About